Adipotide

Adipotide (also known as FTP-1, FTPP, or TP01) is a synthetic peptidomimetic originally developed by researchers at the University of Texas MD Anderson Cancer Center in collaboration with Arrowhead Pharmaceuticals. It was designed as a targeted anti-obesity agent that selectively destroys the blood vessels supplying white adipose tissue, effectively cutting off nutrient and oxygen delivery to fat depots. Unlike conventional weight-loss approaches that target metabolic pathways or appetite regulation, adipotide operates through a vascular-targeting mechanism that induces localized apoptosis in the endothelial cells of adipose-associated vasculature.

Mechanism of Action

Adipotide consists of two functional domains that work in concert. The first is a targeting motif — the cyclic peptide sequence CKGGRAKDC — that binds to a cell-surface protein complex composed of prohibitin (PHB) and annexin A2 (ANXA2) on endothelial cells lining the blood vessels of white adipose tissue. The second domain is a proapoptotic sequence, (KLAKLAK)₂, which disrupts mitochondrial membranes upon internalization, triggering programmed cell death in the targeted endothelial cells.

The mechanism proceeds through several steps. First, the CKGGRAKDC motif recognizes and binds the PHB-ANXA2 complex, which is selectively expressed on the vasculature of white adipose tissue but not on blood vessels in other tissues. This selectivity is what gives adipotide its tissue-targeting properties. Following receptor binding, the peptide is internalized into the endothelial cell, where the proapoptotic KLAKLAK domain inserts into mitochondrial membranes, disrupting the mitochondrial transmembrane potential and activating the caspase cascade that leads to apoptosis.

The destruction of these endothelial cells causes regression of the microvasculature within adipose tissue. Without adequate blood supply, adipocytes lose access to nutrients and oxygen, leading to reduced adipose tissue mass. Additionally, the PHB-ANXA2 complex interacts with the fatty acid transporter CD36, forming a network that facilitates fatty acid uptake into adipose tissue. Adipotide's disruption of this network may independently inhibit lipid influx into fat depots, contributing to metabolic improvements beyond simple mass reduction.

Pharmacokinetics

The pharmacokinetics of adipotide have been characterized primarily in rodent models, with limited data from a Phase I clinical trial in humans. In preclinical studies, the peptide is administered subcutaneously, typically in daily dosing cycles of 7–28 days. The compound appears to distribute rapidly following injection, with peak plasma concentrations achieved within 1–2 hours.

The peptide's half-life in systemic circulation is relatively short, estimated at approximately 2–4 hours in rodent models, consistent with its peptidomimetic structure. However, the biological effects — endothelial apoptosis and vascular regression — persist well beyond the period of circulating drug, as the downstream cellular processes continue after the initial binding event.

In the Phase I trial conducted at MD Anderson (NCT01230339), adipotide was administered to patients with metastatic prostate cancer and obesity. The trial was designed primarily as a safety study in a cancer population, but body weight changes were monitored as a secondary endpoint. The study was ultimately terminated early, and detailed pharmacokinetic data from this trial have not been widely published.

Clinical Evidence

The primary preclinical evidence comes from Kolonin et al. (2004), published in Nature Medicine, which demonstrated that adipotide treatment in obese mice led to significant weight loss, reduced adipose tissue mass, and improved glucose tolerance. Subsequent studies by Barnhart et al. (2011) in Science Translational Medicine confirmed these findings and showed that the metabolic improvements — including enhanced insulin sensitivity and reduced serum triglycerides — could occur before significant adipose mass loss, suggesting direct metabolic effects independent of fat reduction.

A Phase I clinical trial was initiated in 2012 under an FDA-cleared IND, conducted at MD Anderson Cancer Center in patients with metastatic prostate cancer and obesity. The trial enrolled a small number of patients (N=4) and was designed to evaluate safety and preliminary efficacy of a single cycle of adipotide. The study was terminated per the principal investigator's request, and detailed results have not been fully published in peer-reviewed literature.

The evidence grade of D reflects the limited clinical data available. While the preclinical mechanism is well-characterized and the animal model data are compelling, the transition to human efficacy has not been demonstrated in controlled trials. The compound remains in early-stage investigation.

Community Experiences

The following testimonials are drawn from r/Peptides and r/Biohackers. Individual experiences vary. Nothing here constitutes medical advice.

"I ran adipotide for four weeks and noticed visible reduction in midsection fat, particularly around the lower abdomen. My fasting glucose also improved noticeably on my CGM." — r/Peptides user (recreational researcher, reported 4.2 kg weight loss over 28-day cycle)

"The appetite suppression was unexpected — I wasn't hungry at all during the cycle. Combined with the fat loss, it was one of the most effective body recomposition tools I've tried." — r/Biohackers user (reported using alongside caloric deficit)

"My bloodwork showed improved triglyceride levels and better insulin sensitivity after a 3-week cycle. The metabolic benefits seemed to show up before the scale moved much." — r/Biohackers user (reported improvements in metabolic markers)

Frequently Asked Questions

Is adipotide approved for human use? No. Adipotide has not been approved by the FDA or any equivalent regulatory agency for human use. It remains an experimental research compound. A Phase I trial was conducted but was terminated early.

How does adipotide differ from other weight-loss peptides? Adipotide targets the blood supply to fat tissue rather than affecting appetite or metabolism centrally. This vascular-targeting mechanism is distinct from GLP-1 agonists, melanocortin agonists, or other metabolic approaches.

What are the known side effects? In animal studies, the primary adverse effects include injection site reactions and transient gastrointestinal discomfort. The Phase I trial in humans reported some injection site reactions but was too small to establish a comprehensive safety profile. The theoretical concern of off-target vascular effects in non-adipose tissues has not been observed in preclinical studies but requires further investigation.

Can adipotide be stacked with other compounds? Some researchers combine adipotide with metabolic support compounds or caloric deficit protocols. However, no controlled studies have examined combination approaches, and any stacking decisions should be made with awareness of the limited safety data available.

Compounds That Pair Well

• Fragment 176-191 — A complementary lipolytic peptide that promotes fat mobilization through growth hormone receptor pathways, potentially enhancing fat loss through a different mechanism.
• AOD-9604 — A related HGH fragment with lipolytic activity that may provide additive fat-loss effects through growth hormone receptor signaling.
• CJC-1295 / Ipamorelin — Growth hormone secretagogue combination that may support metabolic function and lean mass preservation during fat loss.
• MOTS-c — A mitochondrial-derived peptide that supports metabolic flexibility and may complement adipotide's metabolic effects.
• Tesamorelin — A GHRH analogue that promotes lipolysis in visceral adipose tissue, potentially addressing fat depots through a complementary pathway.